Journal of Neuro-Oncology

, Volume 109, Issue 2, pp 301–307 | Cite as

Population-based survival data for brain tumors in Korea

  • Kyu-Won Jung
  • Heon Yoo
  • Hyun-Joo Kong
  • Young-Joo Won
  • Sohee ParkEmail author
  • Seung Hoon LeeEmail author
Clinical Study


Primary brain tumors are relatively uncommon but particularly lethal cancers. Although survival is useful for monitoring the effects of early cancer detection and treatment, there are few population-based estimates of survival for subjects with brain tumors, especially in Asian countries. Using the Korea National Cancer Incidence Database, 4,721 newly diagnosed cases of histologically confirmed malignant primary brain tumors from 1999 to 2004 were analyzed for observed survival. For trend analyses of glioblastomas, we included 2,751 glioblastoma cases diagnosed between 1999 and 2007. We compared survival by age group and histological type by use of the Kaplan–Meier method. For all ages and all brain tumor types in Korea, five-year survival was 37.5 %. For each histological type of brain tumor survival of pediatric and younger adult populations was much better than that of older adults. Five-year survival for glioblastoma, astrocytoma, anaplastic astrocytoma, and oligodendroglioma was 8.9, 51.6, 25.2, and 73.5 %, respectively. Two-year survival for glioblastoma increased from 18.6 % for cases diagnosed in 1999–2001 to 21.3 % for cases diagnosed in 2002–2004 and to 24.7 % for cases diagnosed in 2005–2007. These results may help clinicians and patients to assess long-term prognoses for brain tumors, and the data presented here could serve as master control data set for single-arm clinical trials, especially in Asian populations.


Brain tumor Cancer registry Epidemiology Survival 



This work was supported by a research grant from the National Cancer Center (no. 1010160).

Conflict of interest

The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.


  1. 1.
    Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Trétarre B, Frappaz D, Henin D, Menei P, Honnorat J, Segnarbieux F (2007) French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 84:189–199PubMedCrossRefGoogle Scholar
  2. 2.
    CBTRUS (2011) Statistical report: primary brain tumors diagnosed in the United States, 2004–2007. The Central Brain Tumor Registry of the United States, HindsdaleGoogle Scholar
  3. 3.
    Kaneko S, Nomura K, Yoshimura T, Yamaguchi N (1993) Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973–1993. J Neurooncol 60:61–69CrossRefGoogle Scholar
  4. 4.
    Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736PubMedCrossRefGoogle Scholar
  5. 5.
    Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results program, 1973 to 2001. Neurosurg Focus 20(4): E1Google Scholar
  6. 6.
    Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43:1–11PubMedCrossRefGoogle Scholar
  7. 7.
    Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Lee JK, Pisani P, Park JG, Members of the Regional Cancer Registries (2005) Nationwide cancer incidence in Korea, 1999–2001; first result using the national cancer incidence database. Cancer Res Treat 37:325–331PubMedCrossRefGoogle Scholar
  8. 8.
    Lee CH, Jung KW, Yoo H, Park SH, Lee SH (2010) Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc 48:145–152PubMedCrossRefGoogle Scholar
  9. 9.
    Gurney JG, Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160–166PubMedCrossRefGoogle Scholar
  10. 10.
    Reis L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Edwards B (2000) SEER Cancer Statistics Review, 1973–1997. National Cancer Institute, Bethesda, MDGoogle Scholar
  11. 11.
    Nomura K (2000) Present status of brain tumor statistics in Japan. Int J Clin Oncol 5:355–360CrossRefGoogle Scholar
  12. 12.
    McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, Menck HR, Laws ER Jr (1998) Factors associated with survival in patients with meningioma. J Neurosurg 88:831–839PubMedCrossRefGoogle Scholar
  13. 13.
    Sant M, Van der Sanden G, Capocaccia R, EUROCARE Working Group (1998) Survival rates for primary malignant brain tumours in Europe. Eur J Cancer 34(14 Spec No):2241–2247PubMedCrossRefGoogle Scholar
  14. 14.
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMedCrossRefGoogle Scholar
  15. 15.
    Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg 99:458–466PubMedCrossRefGoogle Scholar
  16. 16.
    Darefsky AS, King JT Jr., Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8): 2163–2172. doi: 10.1002/cncr.26494 Google Scholar
  17. 17.
    Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1): 207–212. doi: 10.1007/s11060-011-0738-7 Google Scholar
  18. 18.
    Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164PubMedCrossRefGoogle Scholar
  19. 19.
    Scoccianti S, Magrini SM, Ricardi U et al (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67:446–458PubMedCrossRefGoogle Scholar
  20. 20.
    Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedGoogle Scholar
  21. 21.
    Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma (Abstract). Neurooncology 7:369Google Scholar
  22. 22.
    Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR, Perkins WJ, O’Neill BP (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76:677–687PubMedCrossRefGoogle Scholar
  23. 23.
    Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. N Engl J Med 358:18–27PubMedCrossRefGoogle Scholar
  24. 24.
    Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422–1428PubMedCrossRefGoogle Scholar
  25. 25.
    Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS (2004) Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurooncol 6:119–126Google Scholar
  26. 26.
    Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA (2006) Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64:892–897PubMedCrossRefGoogle Scholar
  27. 27.
    Prisco FE, Weltman E, de Hanriot RM, Brandt RA (2002) Radiosurgical boost for primary high-grade gliomas. J Neurooncol 57:151–160PubMedCrossRefGoogle Scholar
  28. 28.
    Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67–74PubMedCrossRefGoogle Scholar
  29. 29.
    Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS (2009) Cancer statistics in Korea: incidence, mortality and survival in 2005. Cancer Res Treat 41:122–131PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  1. 1.Division of Cancer Registration and SurveillanceNational Cancer CenterGoyangRepublic of Korea
  2. 2.Neuro-Oncology ClinicNational Cancer CenterGoyangRepublic of Korea
  3. 3.Department of Epidemiology and Health PromotionYonsei University Graduate School of Public HealthSeoulKorea

Personalised recommendations